RxDoctor Payments Data

Tejesh Patel, MD

Family Medicine · Clinton, WINPI 1447268487

Payments from drug & device makers

$3,309in general payments, 2019–2025

Across 167 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$727
  • Boehringer Ingelheim$587
  • Pfizer$505
  • Lilly USA, LLC$267
  • GSK$267
  • Dexcom, Inc.$237
  • plus $719 from 10 others

What the payments were for

  • Food & beverage$3,20997%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,309 in reported general payments places this provider in the 90th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$63,266
Medicare patients
444
Services billed
828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$56,666
JardianceEmpagliflozin28$29,894
JanuviaSitagliptin Phosphate24$28,673
FarxigaDapagliflozin Propanediol26$16,351
OzempicSemaglutide16$12,626
Lagevrio (Eua)Molnupiravir17$7,513
SynthroidLevothyroxine Sodium19$2,179
Omeprazole170$1,960
Atorvastatin Calcium287$1,850
Oxybutynin Chloride ErOxybutynin Chloride47$1,476
Fenofibrate41$1,256
Metoprolol Succinate95$1,212
Amlodipine Besylate217$1,207
Levothyroxine Sodium151$1,107
Losartan Potassium95$1,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$505$56,66641 claims
MerckJanuvia, Lagevrio (Eua)$150$36,18641 claims
Boehringer IngelheimJardiance$587$29,89428 claims
AstraZenecaFarxiga$727$16,35126 claims
Novo NordiskOzempic$94$12,62616 claims
AbbVieSynthroid$62$2,17919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,482 family medicine providers in Wisconsin.

Other family medicine in Clinton

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →